ETrade Capital Management’s Regeneron Pharmaceuticals REGN Stock Holding History

ETrade Capital Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q3	–	Sell	-346	Closed	-$216K	–	932
2020 Q2	$216K	Sell	346 -343	-50%	-$195K	﹤0.01%	756
2020 Q1	$336K	Buy	+689	New	+$284K	0.01%	564
2019 Q4	–	Sell	-1,663	Closed	-$461K	–	833
2019 Q3	$461K	Buy	1,663 +9	+0.5%	+$2.66K	0.01%	578
2019 Q2	$518K	Buy	1,654 +798	+93%	+$266K	0.01%	551
2019 Q1	$351K	Buy	+856	New	+$352K	0.01%	637

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Polen Capital Management Boca Raton, Florida $14.5B AUM 5.7% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

ETrade Capital Management's REGN Position: Q3 2020 in Review

ETrade Capital Management sold out of Regeneron Pharmaceuticals (REGN) in Q3 2020, closing a stake of 346 shares — an estimated $216K sold.

ETrade Capital Management first reported a position in REGN in Q1 2019 and held it in 5 quarters. The position peaked at $518K in Q2 2019. 908 funds tracked by Wall St. Rank hold REGN as of Q3 2020.

ETrade Capital Management reported no remaining Regeneron Pharmaceuticals position as of Q3 2020 after selling out during the quarter.
ETrade Capital Management sold 346 Regeneron Pharmaceuticals shares in Q3 2020, an estimated $216K.
ETrade Capital Management first reported a position in Regeneron Pharmaceuticals in Q1 2019 and held it in 5 quarters.
ETrade Capital Management's Regeneron Pharmaceuticals position peaked at $518K in Q2 2019.
908 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2020.

Based on ETrade Capital Management's 13F filing for Q3 2020, filed 13 Nov 2020.